Clinical trials
Alcoholic Liver Disease clinical trials
Below are recruiting alcoholic liver disease clinical trials, each written for real people, not researchers. We’re tracking 256 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07370103Recruiting
Predicting low blood pressure in liver disease patients after anesthesia
This study uses an ultrasound to measure blood flow in the neck's main artery to see if it can predict a dangerous drop in blood pressure after you are put to sleep for surgery. It is for adult patients with chronic liver disease who are having planned surgery.
CairoAges 18 years+ - NCT07592013Enrolling by invitation
Ancestry Supplements for Fatty Liver Disease
This study tests whether a special supplement (made from cacao, nopal, and crickets) can help improve fatty liver disease in people with excess body fat. Fatty liver disease happens when fat builds up in the liver, and this trial investigates whether these natural ingredients can reduce that buildup.
Guadalajara, GuadalajaraAges 18–60 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT07313007Recruiting
Gut bacteria chemicals in fatty liver disease
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
Pierre-BéniteAges 18–80 - NCT07530809Recruiting
Time-Restricted Eating for Fatty Liver Disease
This study tests whether eating within a limited time window each day can improve fatty liver disease (a buildup of fat in the liver). If you have moderate-to-advanced fatty liver disease and are overweight, this trial might help you learn if changing when you eat—rather than what you eat—can reduce liver fat and improve your health.
Homburg, SaarlandAges 18–75 - NCT07382349Recruiting
Decision support tools for fatty liver disease
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
Nashville, TennesseeAges 18 years+ - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT04496895Recruiting
Orange peel drink study for reducing body fat
This trial looks at whether a fermented orange peel product can lower body fat in adults. It may help if you have higher body fat and/or fatty liver, and you meet safety and health limits.
Taipei, TaiwanAges 20–65 - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Chandler, ArizonaAges 18–75 - NCT05625750Recruiting
Study of people diagnosed with fatty liver from not-too-much alcohol
This is an observational study for people diagnosed with nonalcoholic fatty liver disease (fatty buildup in the liver not mainly caused by heavy drinking). It may help researchers better understand this condition, especially how it shows up on tests and how people report relevant health information.
Changsha, HunanAges 18–75 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75 - NCT05881005Recruiting
NAC for fatty liver in people with active Cushing’s
This study tests whether NAC (a supplement/medicine) can improve liver health in adults who have active Cushing’s syndrome and fatty liver disease. It may help if your excess stress hormone levels are affecting your liver.
AngersAges 18 years+ - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT06495333Recruiting
Gene and gut bacteria in Hispanic fatty liver patients
This study looks at how a gene variant (PNPLA3) relates to gut bacteria in Hispanic patients with fatty liver disease (MASLD) in Puerto Rico. It aims to understand the connection between your genes, your gut health, and your liver condition.
San JuanAges 21–75 - NCT06564584RecruitingPhase 2
Study of TLC-2716 for high triglycerides and fatty liver disease
This trial tests an investigational drug called TLC-2716 for people with very high triglycerides and a type of fatty liver disease (NAFLD or NASH). The goal is to see if it is safe and can help lower fat levels in the blood and liver.
Guadalajara, JaliscoAges 18–70 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT06634160Recruiting
Fatty liver disease in people with high cholesterol
This study checks how common fatty liver disease is in people with a genetic form of high cholesterol. It may help researchers understand the link between these two conditions.
AngersAges 35 years+ - NCT06984510Recruiting
Early aging and diabetes risk with fatty liver
This study looks at how early biological aging might increase the chance of developing type 2 diabetes in people with a fatty liver (a condition called MASLD). It uses routine health check-up data to understand the link.
Ningbo, ZhejiangAges 20–90 - NCT07051863Recruiting
Non-alcoholic fatty liver disease study with biobank
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
Lugano, Canton TicinoAges 18 years+ - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Birmingham, AlabamaAges 18 years+ - NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT07246421Recruiting
Glucagon resistance in fatty liver and diabetes
This study looks at how people with fatty liver and type 2 diabetes respond to glucagon, a hormone that helps control blood sugar. It may help researchers understand a condition called 'glucagon resistance' and find better treatments.
AarhusAges 30–70
Hear when a new Alcoholic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcoholic liver disease?
- Yes. Clin2 currently lists 256 recruiting alcoholic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcoholic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcoholic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.